Vor Biopharma Inc.
VOR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.05 | -0.12 | -0.15 |
| FCF Yield | -130.98% | -67.05% | -35.59% | -16.91% |
| EV / EBITDA | -0.22 | -1.36 | -2.73 | -4.89 |
| Quality | ||||
| ROIC | -94.31% | -63.63% | -31.80% | -29.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.85 | 0.92 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 1.45% | -8.28% | -28.16% | -80.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | -0.04 | 0.21 | 1.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -85.19 | -72.19 | 0.00 |